Travere Therapeutics (TVTX) EBT (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly EBT came in at -$36.7 million in Q1 2026, up 10.84% YoY from -$33.1 million in Q1 2025, and down 74.33% on a QoQ basis from -$21.1 million in Q4 2025.
Travere Therapeutics (TVTX) EBT (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of EBT data on file, last reported at -$36.7 million in Q1 2026.
- Quarterly EBT rose 10.84% year-over-year to -$36.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.8 million (up 80.17% YoY) and the FY2025 annual result came in at -$49.3 million, up 84.63% from the prior year.
- EBT retreated to -$36.7 million in Q1 2026, from -$21.1 million in the prior quarter.
- In the past five years, EBT ranged from a high of $25.7 million in Q3 2025 to a low of -$135.8 million in Q1 2024.
- A 5-year average of -$65.5 million and a median of -$80.0 million in 2022 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT tumbled 135.75% — and 2025, when it jumped 146.89%.
- Tracing TVTX's EBT over 5 years: stood at -$85.6 million in 2022, then retreated by 3.45% to -$88.5 million in 2023, then soared by 31.84% to -$60.3 million in 2024, then surged by 65.09% to -$21.1 million in 2025, then tumbled by 74.33% to -$36.7 million in 2026.
- The last three EBT figures came in at -$36.7 million (Q1 2026), -$21.1 million (Q4 2025), and $25.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | -35.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -35.00 Mn |
| Mar 31, 2026 | -36.72 Mn |
| Dec 31, 2025 | -21.07 Mn |
| Sep 30, 2025 | 25.71 Mn |
| Jun 30, 2025 | -12.74 Mn |
| Mar 31, 2025 | -41.19 Mn |
| Dec 31, 2024 | -60.34 Mn |
| Sep 30, 2024 | -54.84 Mn |
| Jun 30, 2024 | -69.57 Mn |
| Mar 31, 2024 | -135.77 Mn |
| Dec 31, 2023 | -88.53 Mn |
| Sep 30, 2023 | -89.23 Mn |
| Jun 30, 2023 | -101.87 Mn |
| Mar 31, 2023 | -96.49 Mn |
| Dec 31, 2022 | -85.57 Mn |
| Sep 30, 2022 | -83.92 Mn |
| Jun 30, 2022 | -79.97 Mn |
| Mar 31, 2022 | -81.69 Mn |
| Dec 31, 2021 | -88.77 Mn |
| Sep 30, 2021 | -35.60 Mn |